TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial tests drug for debilitating nerve damage in rare heart condition
Disease control OngoingThis small, early-phase study is testing whether the drug patisiran can help control nerve damage in people with wild-type ATTR amyloidosis, a rare condition where abnormal proteins build up in the body. Ten participants with nerve symptoms will receive patisiran infusions every …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Yale's digital detective: algorithm hunts for hidden heart disease
Diagnosis TerminatedThis study aimed to test a computer algorithm designed to scan medical billing records to find patients who might have ATTR amyloidosis but haven't been diagnosed yet. The goal was to see if this tool could accurately identify these hidden cases, helping doctors find and treat pe…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Yale University • Aim: Diagnosis
Last updated Mar 31, 2026 12:12 UTC
-
New screening program aims to catch rare heart disease earlier
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new screening method to detect a rare heart condition called cardiac amyloidosis earlier in older adults. The research will enroll 800 adults aged 65+ with certain heart conditions or symptoms in primary care clinics in Turkey. Doctors will use a step-by-s…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: Kotyora Family Medicine Health Management and Education Association • Aim: Diagnosis
Last updated Mar 31, 2026 12:11 UTC
-
Doctors probe heart impact of amyloidosis drugs
Knowledge-focused OngoingThis study aims to better understand how two existing drugs, patisiran and vutrisiran, affect the heart in patients with a rare inherited disease called hereditary transthyretin amyloidosis (ATTRv). Researchers will observe 20 patients who have both nerve and heart symptoms and a…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Apr 01, 2026 23:41 UTC